本帖最后由 老马 于 2013-3-13 13:43 编辑
# ]* x0 o# `3 q' I' O! R$ ?5 U6 M
( {1 r" Z1 y3 I' y9 p健择（吉西他滨）+顺铂+阿瓦斯汀
( H/ T9 Y3 `% [* Q; J% h* Q Gemzar +Cisplatin + Avastin) X' `: I- P& V, R( C5 ^
http://annonc.oxfordjournals.org/content/21/9/1804.full
- b2 a) _5 E7 R" cOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' D: w/ F3 q: I2 ^" y+ q5 rPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 {$ ~" Q) W! Z, e4 Z0 y$ gResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: _( ^( x; K& G
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 298)
$ {8 n, |- }7 L& H! {, Q华为网盘附件：# \: o, m+ _+ K4 _
【华为网盘】ava.JPG
7 L1 G, {4 @- Y9 \1 j. [, ]# b |
显身卡
